9 results about "Clostridium difficile (bacteria)" patented technology

The invention discloses a primer group for simultaneously detecting four equine digestive tract bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-8, and the four equine digestive tract bacteria are salmonella enteritidis, salmonella typhimurium, clostridium difficile and lawsonia intracellular. Extracting total DNA (deoxyribonucleic acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; the total DNA is used as a template, and the primer group is used for multiple PCR reaction to obtain an amplification curve. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.

A method of manufacturing ostrich antibodies may include immunizing mature female ostriches with a mixture solution comprising Clostridium difficile toxin A and toxin B, obtaining eggs from the immunized ostriches, and purifying egg yolk antibodies from the eggs.

Bacterial infections evading the current antibiotic arsenal warrant new treatment options. The mainstay treatment for Clostridium difficile infections involves administration of the broad-spectrum antibiotic vancomycin, which also depletes the gut microbiome and its natural defenses. This leads to recurrent C. difficile infections in 20-30% of patients. Alternative treatment options are limited, triggering a perpetual cycle of relapse and recovery that may eventually lead to death. Keratinicyclin B represents a glycopeptide antibiotic chemotype with a mechanism of action that is selective for Clostridia. When combined, vancomycin (or other glycopeptide antibiotic) and keratinicyclin B interact synergistically to inhibit the growth of C. difficile at concentrations far lower than their respective minimal inhibitory concentrations. Such a combination therapy could allow for targeted colonization clearance at low antibiotic doses, thereby minimizing toxicity and reducing the likelihood of relapse.

A bio-sensor device for the electrochemical detection of a bacterial pathogen, the device including a sample chamber and an electronic data module. The sample chamber includes passive sensing probes to detect pathogenic antigens in a sample containing the bacterial pathogen. The probes detect a reaction voltage corresponding to an antigen-antibody reaction occurring when the pathogenic antigens come into contact with an antibody specific for pathogenic antigens present in in the contents of the sample chamber and contacted by the electrical probes. The electronic data module detects and processes electrical signals detected by the conductive electrical probes corresponding to an amount of the antigen present in the sample, wherein the reaction voltage is detected at the time of the reaction.

The present invention relates to a composition comprising a monoclonal antibody binding to Clostridium difficile (C. difficile) for inhibiting a growth of Clostridium difficile (C. difficile), and a use thereof. In addition, the present invention discloses the composition for treating an inflammatory bowel disease, and a use thereof.

The invention discloses a lactobacillus reuteri and a preparation method and application of a microbial inoculum of the lactobacillus reuteri, the lactobacillus reuteri subsp.reuteri OH114 is preserved in Guangdong Province Microbial Culture Collection Center (GDMCC), the preservation address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No.66528, and the preservation time is June 16, 2025. The lactobacillus reuteri newly researched and developed by the invention can effectively inhibit the growth of a plurality of enteropathogenic bacteria such as staphylococcus aureus, escherichia coli, salmonella typhimurium, clostridium difficile, clostridium perfringens, klebsiella pneumoniae, pseudomonas aeruginosa and candida albicans, regulate the balance of intestinal flora, prevent and treat adult diarrhea, and prevent and treat diarrhea. The invention provides a new scheme and way for preventing and treating infectious diarrhea, antibiotic-related diarrhea or irritable bowel syndrome diarrhea.

This document describes compositions, methods, and kits for detecting diarrheal pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for a multiplex polymerase chain reaction (PCR)-based assay for detecting gastrointestinal pathogens such as adenovirus, astrovirus, rotavirus, norovirus, zaruzin virus, Campylobacter species, Clostridium difficile, enteroaggregative Escherichia coli (EAEC), enteropathogenic Escherichia coli (EPEC), enterotoxin-producing Escherichia coli (ETEC), Shigella-like toxin-producing Escherichia coli (STEC), Shigella spp. / enteroinvasive Escherichia coli (EIEC), Escherichia coli O157, Listeria monocytogenes, Shigella-like bacteria, Salmonella spp., Yersinia enterocolitica, Vibrio species, Cryptosporidium species, Cyclospora kayanoides, Entamoeba histolytica, Giardia lamblia, or Giardia lamblia. Other embodiments include methods and kits for detecting gastrointestinal pathogens.

The application discloses a lactobacillus rhamnosus A21174 for inhibiting infection of multi-drug resistant strains and clostridium difficile, and application thereof. The lactobacillus rhamnosus A21174 has obvious inhibiting effect on drug-resistant staphylococcus aureus, pseudomonas aeruginosa, drug-resistant escherichia coli, drug-resistant acinetobacter baumannii and a model strain of clostridium difficile. Compared with a commercial strain of lactobacillus rhamnosus, the lactobacillus rhamnosus A21174 has better bacteriostatic effect on clostridium difficile. The lactobacillus rhamnosus A21174 also shows good effect in in-vivo and in-vitro experiments such as resistance to artificial gastric and intestinal fluid, resistance to bile salt, anti-aging, anti-oxidation, improvement of cognition and the like, and therefore, the strain can be used as a probiotic agent to prepare a product for regulating intestinal flora, and has important significance for preventing and / or treating diseases caused by infection of multi-drug resistant bacteria, clostridium difficile and pseudomonas aeruginosa.

The invention relates to the field of microorganisms, and discloses a microbial agent for inhibiting growth of clostridium difficile and enterococcus faecalis and application of the microbial agent. The microbial agent is prepared from bifidobacterium longum, lactobacillus delbrueckii subsp. Bulgaricus, bifidobacterium breve, lactobacillus reuteri, ackermann mucilaginosus and bacteroides ovatus. The six strains in the microbial inoculum cooperate to form a thick and dense symbiotic biological membrane, the thick and dense symbiotic biological membrane is rapidly planted in a symbiotic system of clostridium difficile (CD) and enterococcus faecalis (EF), a physical barrier is constructed, and colonization and diffusion of the clostridium difficile (CD) and the enterococcus faecalis (EF) are spatially inhibited; meanwhile, the content of leucine and ornithine secreted by EF in a system is remarkably reduced through metabolism synergy, cross-breeding of the leucine and the ornithine is blocked, growth is inhibited, CD spore germination can be inhibited by 100%, CD toxin secretion is reduced, the yield of pathogenic symbiotic biological membranes is reduced, CD pathogenicity is weakened in multiple links, all-around intervention on co-infection of CD and EF is achieved, and the application prospect is wide. And an efficient and safe solution is provided for the clinical problem.